Entera Bio Ltd. (ENTX)
Company Description
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs.
The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures.
The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses.
Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
| Country | IL |
| IPO Date | Jun 28, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 18 |
| CEO | Miranda J. Toledano M.B.A. |
Contact Details
Address: Kiryat Hadassah Minrav Building Jerusalem, IL | |
| Website | https://www.enterabio.com |
Stock Details
| Ticker Symbol | ENTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001638097 |
| CUSIP Number | M40527109 |
| ISIN Number | IL0011429839 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Miranda J. Toledano M.B.A. | Chief Executive Officer & Director |
| Dana Yaacov-Garbeli CPA | Chief Financial Officer |
| Dr. Hillel Galitzer M.B.A., Ph.D. | Chief Operating Officer |
| Dr. Gregory Burshtein Ph.D. | Chief of Research & Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 28, 2025 | 10-K | Annual Report |
| Mar 28, 2025 | 8-K | Current Report |
| Mar 17, 2025 | 8-K | Current Report |
| Jan 17, 2025 | 4 | Filing |
| Jan 17, 2025 | 4 | Filing |
| Jan 17, 2025 | 4 | Filing |
| Jan 17, 2025 | 4 | Filing |
| Jan 17, 2025 | 4 | Filing |
| Jan 10, 2025 | 8-K | Current Report |
| Jan 10, 2025 | 424B5 | Filing |